- Home
- ENSC vs SOND Comparison
ENSC vs SOND Comparison
Compare ENSC & SOND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- SOND
- Stock Information
- Founded
- ENSC 2003
- SOND 2014
- Country
- ENSC United States
- SOND United States
- Employees
- ENSC N/A
- SOND N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- SOND Hotels/Resorts
- Sector
- ENSC Health Care
- SOND Consumer Discretionary
- Exchange
- ENSC Nasdaq
- SOND Nasdaq
- Market Cap
- ENSC 6.4M
- SOND 6.8M
- IPO Year
- ENSC N/A
- SOND N/A
- Fundamental
- Price
- ENSC $1.68
- SOND $0.13
- Analyst Decision
- ENSC
- SOND
- Analyst Count
- ENSC 0
- SOND 0
- Target Price
- ENSC N/A
- SOND N/A
- AVG Volume (30 Days)
- ENSC 79.2K
- SOND 42.6M
- Earning Date
- ENSC 11-14-2025
- SOND 10-14-2025
- Dividend Yield
- ENSC N/A
- SOND N/A
- EPS Growth
- ENSC N/A
- SOND N/A
- EPS
- ENSC N/A
- SOND N/A
- Revenue
- ENSC $4,487,973.00
- SOND $589,133,000.00
- Revenue This Year
- ENSC N/A
- SOND $46.47
- Revenue Next Year
- ENSC N/A
- SOND N/A
- P/E Ratio
- ENSC N/A
- SOND N/A
- Revenue Growth
- ENSC 1.51
- SOND N/A
- 52 Week Low
- ENSC $1.53
- SOND $0.08
- 52 Week High
- ENSC $10.96
- SOND $4.09
- Technical
- Relative Strength Index (RSI)
- ENSC 30.16
- SOND 24.33
- Support Level
- ENSC $1.53
- SOND $0.08
- Resistance Level
- ENSC $2.17
- SOND $0.23
- Average True Range (ATR)
- ENSC 0.14
- SOND 0.09
- MACD
- ENSC -0.04
- SOND -0.00
- Stochastic Oscillator
- ENSC 24.81
- SOND 7.87
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About SOND Sonder Holdings Inc.
Sonder Holdings Inc is engaged in providing short and long-term accommodations to travelers in various cities across North America, Europe, and the Middle East. The Sonder units in each apartment-style building and each hotel property are selected, designed, and managed directly by the Company. The Company generates revenues by providing short-term or month-to-month accommodations to its guests. The Company also provides accommodations to travelers through boutique hotels.